August 18, 2022 – Marco Quarta, Ph.D., will present the latest research on the topic “From Single Cell AI-enabled Discovery of Cellular Senescence to Targeted Senolytic Drug Development” at the world’s largest annual Aging Research and Drug Discovery conference (9th ARDD). Dr. Quarta is the CEO and Co-founder at Rubedo Life Sciences.
Marco co-founded and leads Rubedo Life Sciences driving its mission to develop treatments for age-related diseases and extend healthspan by selectively targeting pathological cells involved in the biological aging process. As a scientist, he earned a Masters degree in Biotechnology, a PhD in Neuroscience, and post-doctoral training in Aging and Stem Cells Biology in the lab of his mentor Prof. Thomas Rando at Stanford University School of Medicine. He then directed at Stanford/VA Hospital Palo Alto a research team focused on translational medical research in the fields of aging and regenerative medicine. He is backed by over 20 years of research with a track record of scientific publications in top tier journals. Marco is an inventor and entrepreneur, he co-founded and led the international biotech umbrella organization Young European Biotech Network (YEBN), and later joined the European Federation of Biotechnology (EFB) executive board.
Marco Quarta founded and led the biotech company “WetWare Concepts” in Europe. In California, with the Stanford colleague Prof. Vittorio Sebastiano he also co-founded “Turn Biotechnologies” based on their work on epigenetic reprogramming of cellular aging, where he served as CSO and he is a Board Director. Quarta sits on the advisory board of the California Institute for Regenerative Medicine (CIRM) – Calpoly program in regenerative medicine. He is in the advisory and research board at the Center for Healthcare Innovation (CHI). He is a member of the Paul F Glenn Center for the Biology of Aging Studies at Stanford University. Quarta keeps fostering and championing high standards of compliance, ethics and patient safety in the development of innovative translational therapeutics, putting patients and society at the center of all actions.
The conference proceedings of the ARDD are commonly published in peer-reviewed journals with the talks openly available at www.agingpharma.org. Please review the conference proceedings for 2019, 2020 and 2021https://www.aging-us.com/article/203859/text .
“Aging is emerging as a druggable condition with multiple pharmaceuticals able to alter the pace of aging in model organisms. The ARDD brings together all levels of the field to discuss the most pressing obstacles in our attempt to find efficacious interventions and molecules to target aging. The 2022 conference is the best yet with top level speakers from around the globe. I’m extremely excited to be able to meet them in person at the University of Copenhagen in late summer.” said Morten Scheibye-Knudsen, MD, Ph.D., University of Copenhagen.
“Aging research is growing faster than ever on both academia and industry fronts. The ARDD meeting unites experts from different fields and backgrounds, sharing with us their latest groundbreaking research and developments. Our last ARDD meeting took place both offline and online, and it was a great success. I am particularly excited that being a part of the ARDD2022 meeting will provide an amazing opportunity for young scientists presenting their own work as well as meeting the experts in the field.” said Daniela Bakula, Ph.D., University of Copenhagen.
“Many credible biopharmaceutical companies are now prioritized aging research for early-stage discovery or therapeutic pipeline development. It is only logical to prioritize therapeutic targets that are important in both aging and age-associated diseases. The patient benefits either way. The best place to learn about these targets is ARDD, which we organize for nine years in a row. This conference is now the largest in the field and is not to be missed”, said Alex Zhavoronkov, Ph.D., founder and CEO of Insilico Medicine and Deep Longevity.
Building on the success of the ARDD conferences, the organizers developed the “Longevity Medicine” course series with some of the courses offered free of charge at Longevity.Degree covered in the recent Lanced Healthy Longevity paper titled Longevity medicine: upskilling the physicians of tomorrow.
About Aging Research for Drug Discovery Conference
At ARDD, leaders in the aging, longevity, and drug discovery field will describe the latest progress in the molecular, cellular and organismal basis of aging and the search for interventions. Furthermore, the meeting will include opinion leaders in AI to discuss the latest advances of this technology in the biopharmaceutical sector and how this can be applied to interventions. Notably, this year we are expanding with a workshop specifically for physicians where the leading-edge knowledge of clinical interventions for healthy longevity will be described. ARRD intends to bridge clinical, academic and commercial research and foster collaborations that will result in practical solutions to one of humanity's most challenging problems: aging. Our quest? To extend the healthy lifespan of everyone on the planet.
About Scheibye-Knudsen Lab
In the Scheibye-Knudsen lab we use in silico, in vitro and in vivo models to understand the cellular and organismal consequences of DNA damage with the aim of developing interventions. We have discovered that DNA damage leads to changes in certain metabolites and that replenishment of these molecules may alter the rate of aging in model organisms. These findings suggest that normal aging and age-associated diseases may be malleable to similar interventions. The hope is to develop interventions that will allow everyone to live healthier, happier and more productive lives.
About Deep Longevity
Deep Longevity has been acquired by Edurance RP (SEHK:0575.HK), a publicly-traded company. Deep Longevity is developing explainable artificial intelligence systems to track the rate of aging at the molecular, cellular, tissue, organ, system, physiological, and psychological levels. It is also developing systems for the emerging field of longevity medicine enabling physicians to make better decisions on the interventions that may slow down, or reverse the aging processes. Deep Longevity developed Longevity as a Service (LaaS)© solution to integrate multiple deep biomarkers of aging dubbed "deep aging clocks" to provide a universal multifactorial measure of human biological age. Originally incubated by Insilico Medicine, Deep Longevity started its independent journey in 2020 after securing a round of funding from the most credible venture capitalists specializing in biotechnology, longevity, and artificial intelligence. ETP Ventures, Human Longevity and Performance Impact Venture Fund, BOLD Capital Partners, Longevity Vision Fund, LongeVC, co-founder of Oculus, Michael Antonov, and other expert AI and biotechnology investors supported the company. Deep Longevity established a research partnership with one of the most prominent longevity organizations, Human Longevity, Inc. to provide a range of aging clocks to the network of advanced physicians and researchers. https://longevity.ai/
About Endurance RP (SEHK:0575.HK)
Endurance RP is a diversified investment group based in Hong Kong currently holding various corporate and strategic investments focusing on the healthcare, wellness and life sciences sectors. The Group has a strong track record of investments and has returned approximately US$298 million to shareholders in the 21 years of financial reporting since its initial public offering. https://www.endurancerp.com/